For your adult patients with major depressive disorder (MDD) as adjunctive therapy with antidepressants
Add CAPLYTALyte upnext-level MDD reliefvs. antidepressant alone1
Help push beyond the shadows of partial response in MDD and add CAPLYTA to your patient's antidepressant
Major Depressive Disorder (Adjunctive)
Ready to add CAPLYTA?
In Major Depressive
disorder (Adjunctive):
Superior depression symptom relief in MDD patients with or without symptoms of anxiety* compared to an antidepressant alone at 6 weeks1
- Based on change from baseline in MADRS total score
Well-established safety and tolerability profile1
- The most common adverse reactions (≥5% of patients exposed to CAPLYTA and greater than twice the rate of placebo) were dizziness, dry mouth, somnolence/sedation, nausea, fatigue, and diarrhea
- Consistent across all indications—aMDD, BP I & II depression (as monotherapy and adjunctive therapy with lithium or valproate), and schizophrenia
Sustained treatment over 6 months2†
- 85% stayed on CAPLYTA during the 6‑month, open‑label safety trial
- *CAPLYTA is not approved for the treatment of anxiety disorders. Symptoms of anxiety in patients with MDD are based on DSM-5 criteria for anxious distress.
- †Limitation: This open-label safety extension trial was designed primarily to assess long-term safety and tolerability. Efficacy outcomes are exploratory and should be interpreted with caution, as the study was not powered or controlled to assess treatment efficacy.
- aMDD=adjunctive major depressive disorder; BP=bipolar; DSM=Diagnostic and Statistical Manual of Mental Disorders; MADRS=Montgomery-Åsberg Depression Rating Scale; MDD=major depressive disorder.
Only CAPLYTA has proven efficacy and safety
across 5 depression indications1,3-9‡
FDA-Approved Depression
Indications for adults
| Major Depressive DisorderAdjunctive with an antidepressant | Bipolar I DepressionMonotherapyAdjunctive with lithium or valproate | Bipolar II DepressionMonotherapyAdjunctive with lithium or valproate | |||
|---|---|---|---|---|---|
| CAPLYTA |  | | | | |
| Cariprazine |  | | |||
| Brexpiprazole | | ||||
| Olanzapine/ Fluoxetine§ | | ||||
| Quetiapine/ Quetiapine XR | | | | ||
| Lurasidone | | | |||
| Aripiprazole | | ||||
Swipe table for more
| CAPLYTA | Cariprazine | Brexpiprazole | Olanzapine/ Fluoxetine|| | Quetiapine/ Quetiapine XR | Lurasidone | Aripiprazole | |
|---|---|---|---|---|---|---|---|
| MDD | |||||||
| Adjunctive Therapy§ | | | | | | ||
| Bipolar I Depression | |||||||
| Monotherapy | | | | | | ||
| Adjunctive Therapy¶ | | | |||||
| Bipolar II Depression | |||||||
| Monotherapy | | | | ||||
| Adjunctive Therapy¶ | |
There are no head-to-head clinical studies comparing the safety and efficacy of these products. This chart does not represent all approved indications for each product.
- ‡Among antipsychotics.
- §With an antidepressant.
- ¶With lithium or valproate.
- §Olanzapine/fluoxetine is indicated for treatment resistant depression which is not shown.
- MDD=major depressive disorder.
